Acomplia Online - The New Weight Loss Drug

Acomplia is also known as Rimonabant - the latest weight loss drug to hit the UK and European health care markets is making waves across the world. Increasing number of over weight and obese people are turning to Acomplia for help with their weight loss efforts. Acomplia has now also gone online and all details about the drug can be found via www.rimonabant-acompli.co.uk.

Acomplia Rimonabant is a weight loss drug from Sanofi-Aventis that helps over weight and obese people lose weight quickly and safely in combination with diet and exercise regimen. Patients who would like to start on an Acomplia treatment can find all information they need about the drug by searching for Buy Acomplia. There are multiple resources available which provide good guidance about Buy Acomplia.

Acomplia (Rimonabant) is presently approved for prescription only in the UK and Europe. Sanofi-Aventis has filed for approval with the FDA for selling the drug in the US but is yet to get the green signal.

Following its launch, Acomplia has become the favorite weight loss drug for obese patients and is in high demand everywhere. This has led to the development of several resources, which provide Acomplia online. These resources don’t just allow you to buy Acomplia online but also give you all necessary information including dosage, safety, side effects and new developments regarding Acomplia.

If you are just trying to get more details about Acomplia, some of the best sites for finding information about Acomplia online include www.buy-acomplia.co.uk. If on the other hand you would like to buy Acomplia online, you would need a valid prescription from your doctor before you can buy it. You can also do an online consultation with a doctor for getting Acomplia prescribed and this can be done through a couple of sites such as www.rimonabant-acomplia.co.uk .

Order Acomplia Rimonabant UK for weight loss and obesity.

Benefits of Rimonabant

        Rimonabant’s benefits are by helping to reduce appetite, and thus help those who use the drug lose weight. There is also hope that Acomplia will help the health of patients in other ways. There is also evidence that it helps with lipid levels (such as cholesterol) in the blood and might help with other metabolism-related health problems, as well as help smokers quite smoking.
Rimonabant Acomplia drug in a clinical test, helps you lose weight and it also helps protect your heart in many ways. Trials have shown that 33% of people on Rimonabant Acomplia lost 10% of body weight and kept their weight down for two years - this is a record, no other diet drug has managed to keep a person’s weight down for so long. A weight loss of 5 to 10 percent can significantly improve risk factors for obesity-related diseases and delay or prevent type 2 diabetes in persons at high risk.

Buy Rimonabant Acomplia today and start losing weight.

Why to buy Rimonabant (Acomlpia)??

Buy Acomplia Rimonabant, a magic pill for treating obesity. This oral prescription Rimonabant Acomplia an anti obesity drug has been made saleable in the UK and rest of the Europe from 28st June 2006.Buy Rimonabant acomplia which is available in 20mg tablets. which is to consumed daily as per your doctor’s prescription. Clinical studies have also recognized the rimonabant to be helpful in reducing fat. Buy rimonabant a diet pill for weight loss. Now you can buy rimonabant online in UK and get next day delivery

How does it work?

Acomplia tablets contain the active ingredient rimonabant, which is a type of medicine called a cannabinoid-1 receptor antagonist. It is used to aid weight loss in people who are obese or overweight.

Rimonabant works by blocking receptors called cannabinoid-1 receptors (CB1). These are found in the brain, fat tissue, digestive system, liver and muscles.

The CB1 receptors are part of a system in the body called the endocannabinoid system. This system has only recently been discovered and explored. It is involved in regulating energy balance, sugar and fat metabolism and body weight.

The CB1 receptors found in a particular area of the brain called the mesolimbic system are involved in controlling our intake of highly palatable, sweet or fatty foods. Overactivation of the CB1 receptors is associated with increased appetite, cravings for food and fat build-up.

Rimonabant blocks CB1 receptors and so reduces cravings for these types of foods and helps decrease appetite and control hunger.

Recent two year study involving Rimonabant (Acomplia) diet pill, The Rimonabant Side effects for those who taking Rimonabant Acomplia, were mild. Some of the side effects of Rimonabant (acomplia) included irritability, depression, and nausea. Acomplia is such a new drug which has few side effects with compare to advantages. As with all drugs, come risks. With obesity come risks. Do the risks from obesity outweigh the risks involved with Rimonabant (acomplia) diet pill? These are questions that the dieter should discuss with their doctors.

Purchase Rimonabant diet pill and start weight loss from today. click here to Order Rimonabant

Buy Rimonabant Acomplia - an anti obesity drug for quick weight loss online. Some tests of Rimonabant conducted on humans since last two years have shown significant results on losing weight through rimonabant acomplia pill.

In the most recent trial of rimonabant acomplia, 1507 overweight and obese patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day.). Patients taking 20 mg rimonabant had significant weigh loss, and also improvement in lipid profiles, compared to patients on placebo. (Those taking 5 mg of Rimonabant doses also had more weight loss than placebo patients, but the magnitude of weight loss was much less.) In addition, waist measurements significantly improved in rimonabant acomplia patients. There are so many advantages of rimonabant to know.

In the first study of Rimonabant Acomplia, designed to measure the drug’s ability to induce weight loss, 44% of patients who took rimonabant acomplia for 1 year lost more than 10% of their body weight.

Furthermore, Patients treated with rimonabant acomplia tended to have increased HDL cholesterol levels (i.e., the “good” cholesterol) and reduced triglyceride levels.

Studies show that Rimonabant (acomplia) is used to reduce appetite, and thus rimonabant helps the patient who suffers from obesity. Rimonabant also help the patient in metabolism- related health problems.

Order Rimonabant Acomplia online and get a well shaped body today.

How Rimonabant Acomplia works?

• Rimonabant Acomplia is the first of a class of drug, called CB1 blockers, that act on the endocannabinoid system (the EC system), a natural system that modulates the body’s energy balance and nicotine dependence. An over-stimulated EC system is thought to play a role in obesity, and CB1 blockers are supposed to reduce this overstimulation for food intake.

• There are nerve receptors that exist in the brain and fat cells. These receptors tell the body to overeat. Rimonabant Acomplia blocks the signals these receptors give out - it stops them from telling us to overeat. Overeaters have very active receptors of this kind. By blocking the signals, the overeater does not have the same urge to eat. There is no other drug like Rimonabant Acomplia which helps you stop overeating.

Order Rimonabant Acomplia online from here and see the wonder of Rimonabant over obesity and overweight today !

Rimonabant Acomplia an anti obesity drug

Rimonabant acomplia is an anti-obesity drug now available in UK. Rimonabant acomplia has been hailed by some doctors on the basis of Rimonabant clinical trials as a major breakthrough in treating obesity.

Rimonabant Acomplia is a diet pill used for the weight loss. Rimonabant acomplia is available online in 20mg pill.which can be available online in UK from rimonabantonline.org. Rimonabant acomplia is a miracle drug for the patient of obesity. It have been proved that patient whose BMI is greater than 30 can buy Rimonabant acomplia online as prescribe bye our doctor and loss their weight effectively.

How does Rimonabant Acomplia works??

Acomplia is the brand name of Rimonabant has been developed by the French Pharmaceutical company Sanofi-Synthelabo to control the obesity in human body. Rimonabant Acomplia has been created to act not only on the mechanism of the human brain but also simultaneously it acts on the nerve cells that control the energetic mechanism of the body. Rimonabant–acomplia is currently in the third phase of study in France, which proved that the drug stop those signals of the brain that generates the feeling of hunger. By this, the patients will not take large quantity of food and naturally the weight starts to fall.It has been proved in Rimonabant clinical trials that rimonabant is most effective diet pill for the weight management. There are lots of other advantages also to use Rimonabant acomplia.

Rimonabant acomplia is available online in all over UK.To get Rimonabant Acomplia online click here Order rimonabant

Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity

 Buy Acomplia  online for TREATMENT OF OBESITY

Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.

“Acomplia is a selective CB1 endocannabinoid receptor antagonist.”

It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.

Obesity is now the most common nutritional disorder in western industrialised countries and arises from the accumulation of excess fat in the body from over consumption of fatty foods. 

Data from the World Health Organisation’s MONICA project show that in some parts of Europe over 70% of men aged 55-64 years are clinically obese or overweight (BMI >25) and almost 70% of women in this age group. One in five of all Americans is obese and one in three overweight. Furthermore, increasing rates of childhood obesity are likely to exacerbate the trend towards increasing obesity in adulthood.

“The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption.”

There is a strong association between obesity and increased risk of cardiovascular disease and diabetes and possibly certain cancers, such as breast and colorectal cancer.

The dramatic rise in the incidence of type 2 diabetes is due largely to the increased prevalence of obesity. Increases in body weight lead to changes in blood lipid and cholesterol levels, predisposing to increased risk of atherosclerosis.

THERAPEUTIC APPROACHES TO TREATMENT OF OBESITY

Not surprisingly, the growing prevalence of obesity has stimulated the search for drugs to treat this condition. Various therapeutic strategies have been explored, including:

• Serotonin and noradrenaline reuptake inhibitors (anorectic agents)
• Lipase inhibitors
• ß 3-adrenoreceptor agonists
• Leptin agonists
• Melanocortin-3 agonists

Sanofi-Aventis’ approach is completely different to the above. It developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as “the munchies”. Sanofi-Aventis worked on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.

The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption and the phenomena of dependence / habituation. To develop suitable drugs against this target, the human cannabinoid receptor was first cloned and then expressed in cells.

Compounds with potential inhibitory activity against this receptor were then screened for inhibitory activity. Rimonabant emerged from this screening process as a potent CB1 receptor antagonist. Preclinical animal studies subsequently showed that it could reduce consumption of fats and sugars, which contribute to weight gain.

PHASE III DATA HIGHLIGHT EFFICACY AND SAFETY

The promising preclinical findings with Acomplia (rimonabant) have been confirmed in a series of clinical studies, including pivotal phase III trials involving over 6,000 obese subjects that were carried out in both the US and Europe.

Two-year data from the phase III multicentre Rimonabant In Obesity (RIO) trials, which compared rimonabant at doses of 5mg and 20mg with placebo with respect to weight reduction and prevention of weight gain, showed that the positive results seen after a year’s treatment were sustained over the full two-year trial period.

“There is a strong association between obesity and increased risk of cardiovascular disease, diabetes and possibly certain cancers.”

Consistent with the one-year data, the results showed that overweight and obese patients taking rimonabant 20mg/d achieved significant reductions in body weight, waist circumference (an indicator of abdominal obesity) and improved lipid and glycaemic profiles compared with placebo recipients. Rimonabant also had a significant impact on metabolic CVD risk factors, greater than that expected by weight loss alone.

Efficacy and safety in long-term use is important feature of any antiobesity drug. Some potential antiobesity medications have proved effective in the first six months of treatment only to lose effectiveness as subjects develop resistance to treatment.

Data from the RIO trials suggest rimonabant is effective for maintaining weight loss for periods of at least two years. Long-term safety is also a major concern. In the US, the FDA generally requires two years of safety data before approving antiobesity drugs.

Results from the phase III RIO trial programme suggest rimonabant is well tolerated in long-term use. Among patients who were randomly assigned to continue their first-year treatment for a second year, 6.7%, 8.3% and 6.0% discontinued from the placebo, rimonabant 5mg and 20mg groups respectively.

The ongoing phase IIIb trial programme for rimonabant includes studies in patients with diabetes (SERENADE), dyslipidaemia (ADAGIO) and cardiovascular disease (STRADIVARIUS, AUDITOR, CRESCENDO).

“There is a strong association between obesity and increased risk of cardiovascular disease, diabetes and possibly certain cancers” so Buy Acomplia for TREATMENT OF OBESITY now !

Clinical Tests of Acomplia

The use of Acomplia as a treatment to aid weight loss received a letter of approval from the FDA . It also has passed other testing as well. All this testing has been going on for some time, as described below. However, on February 17, 2006, the FDA declined to issue final approval in early 2006 as hoped until a number of issues were resolved.

Recent Testing Developments

Obesity is now the most common nutritional disorder in western industrialised countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from over consumption of fatty foods. Prevalence of obesity in the US and Europe has reached epidemic levels.

In March, 2006, compiled data from four trials that were part of the “Rimonabant (Acomplia/Zimulti) in Obesity and Related Metabolic Disorders” (RIO) program was released. Surprisingly, Acomplia’s beneficial effect on blood sugars and fats went 57 percent beyond the benefit that would have been expected from weight loss alone. The drug, which affects the body’s cannabinoid system, appears to reduce interrelated risks for heart and metabolic diseases.

The Rimonabant In Obesity (RIO) Study

The RIO study involved more than 6,000 patients worldwide. Results from the RIO programme demonstrated that one Acomplia 20 milligram tablet taken every day significantly decreased weight and waist circumference, HbA1c, and triglycerides and increased HDL-cholesterol levels. Importantly, the label granted by the European Commission states that an estimated 50 percent of the observed improvements in HbA1c, HDL-cholesterol and triglycerides were beyond that expected from weight loss alone.

The RIO study was conducted in several global locations. The primary focus was measuring weight loss after one year of Acomplia intake with a controlled diet. The secondary focus was on risk factors related to obesity and metabolism.

The primary objective of the trial was to assess weight loss over one year, and then to determine the ability of Acomplia to prevent regaining weight during a second year of treatment. Results were positive and researchers concluded that safety concerns were minimal.

Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette pangs more manageable.

In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease.

Dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the patients diagnosed at the start of the study with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.

Alcohol Use Reduction

In March, 2006, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) began recruiting participants for a test on the possible use of rimonabant to reduce alcohol consumption.

This research shows patients who took 20 mg rimonabant (Acomplia/Zimulti) for 1 year were then re-randomized to either continue on rimonabant (Acomplia/Zimulti), or to switch to placebo. Patients who stayed on rimonabant for the second year did not lose additional weight, while those switched to placebo gained weight. At the end of 2 years, patients who took rimonabant for one year and placebo for the second year had about the same amount of overall weight loss as patients who took placebo from the beginning.

Buy Rimonabant (Acomplia)Online

Rimonabant (Acomplia), discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being sold under the trade name Acomplia and under the name as Zimulti in USA.

How Acomplia/Rimonabant/Zimulti Works?

Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette pangs more manageable.

In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease.

Dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the patients diagnosed at the start of the study with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.

How can I buy Rimonabant-Acomplia ?

Buy Acomplia with us for eliminating unnecessary fats from the body and smoking habit. http://www.rimonabant-acomplia.co.ukoffers a wide range of Rx and Over the Counter drugs at the most substantial prices. Uplift your self esteem and confidence with Acomplia. Buy Acomplia and lessen the chance of cardiovascular diseases.

Acomplia Rimonabant has been approved as a new weight loss drug in a lot of European countries. It is available in many European countries and can be bought online by the consumers from US.

Buying Rimonabant Acomplia helps you to treat obesity but this new class weight loss drug Rimonabant Acomplia is not yet approved for smoking cessation. It is still waiting for the approval from European union for smoking cessation.

Order Acomplia Rimonabant

What is Rimonabant?

Rimonabant is the antismoking, slimming super-drug for the new generation. Rimonabant (Acomplia) helps in losing weight. Approximately two thirds of the U.S. adults have been found to be overweight or obese, which greatly increases the risk of developing diabetes mellitus and cardiovascular disease and death from related causes.

The number of people who are obese is rising at a very fast rate. About 1.2 billion people in the world are overweight and at least 300 million of them are obese, even though obesity is said to be one of the 10 most preventable health risks, according to the findings of World Health Organization.

If you are one of them - it’s high time you Order Rimonabant online.